Concord Biotech Limited

rs,

1 Symbol: CONCORDBIO To General Manager, Listing Department BSE Limited Phiroze Jeejabhoy Towers, Dalal Street, Mumbai – 400 001 Scrip Code: 543960 Dear Sir/Ma’am, Sub.: Investor’s Presentatio

10%

25 Consolidated Financial Highlights Revenue (Rs. in Crs) EBITDA (Rs. in Crs) PAT (Rs. in Crs) +10% 698.0 770.2 +6% 297.3 315.9 +9% 213.1 231.3 +1% 240.8 244.2 -8% 105.9 98.0 -2% 77.6

6%

ncial Highlights Revenue (Rs. in Crs) EBITDA (Rs. in Crs) PAT (Rs. in Crs) +10% 698.0 770.2 +6% 297.3 315.9 +9% 213.1 231.3 +1% 240.8 244.2 -8% 105.9 98.0 -2% 77.6 75.9 Q3FY24 Q3F

9%

evenue (Rs. in Crs) EBITDA (Rs. in Crs) PAT (Rs. in Crs) +10% 698.0 770.2 +6% 297.3 315.9 +9% 213.1 231.3 +1% 240.8 244.2 -8% 105.9 98.0 -2% 77.6 75.9 Q3FY24 Q3FY25 9MFY24 9MFY25

1%

EBITDA (Rs. in Crs) PAT (Rs. in Crs) +10% 698.0 770.2 +6% 297.3 315.9 +9% 213.1 231.3 +1% 240.8 244.2 -8% 105.9 98.0 -2% 77.6 75.9 Q3FY24 Q3FY25 9MFY24 9MFY25 Q3FY24 Q3FY25 9

8%

s) PAT (Rs. in Crs) +10% 698.0 770.2 +6% 297.3 315.9 +9% 213.1 231.3 +1% 240.8 244.2 -8% 105.9 98.0 -2% 77.6 75.9 Q3FY24 Q3FY25 9MFY24 9MFY25 Q3FY24 Q3FY25 9MFY24 9MFY25 Q3FY

2%

s) +10% 698.0 770.2 +6% 297.3 315.9 +9% 213.1 231.3 +1% 240.8 244.2 -8% 105.9 98.0 -2% 77.6 75.9 Q3FY24 Q3FY25 9MFY24 9MFY25 Q3FY24 Q3FY25 9MFY24 9MFY25 Q3FY24 Q3FY25 9MFY24

190 bps

MFY25 Q3FY24 Q3FY25 9MFY24 9MFY25 Gross Profit Margin (%) EBIDTA Margin (%) PAT Margin (%) -190 bps -290 bps 80.4% 78.5% 79.9% 77.0% -390 bps -160 bps 44.0% 40.1% 42.6% 41.0% -110 bps -5

290 bps

Y24 Q3FY25 9MFY24 9MFY25 Gross Profit Margin (%) EBIDTA Margin (%) PAT Margin (%) -190 bps -290 bps 80.4% 78.5% 79.9% 77.0% -390 bps -160 bps 44.0% 40.1% 42.6% 41.0% -110 bps -50 bps 32.

80.4%

25 9MFY24 9MFY25 Gross Profit Margin (%) EBIDTA Margin (%) PAT Margin (%) -190 bps -290 bps 80.4% 78.5% 79.9% 77.0% -390 bps -160 bps 44.0% 40.1% 42.6% 41.0% -110 bps -50 bps 32.2% 31.

78.5%

Y24 9MFY25 Gross Profit Margin (%) EBIDTA Margin (%) PAT Margin (%) -190 bps -290 bps 80.4% 78.5% 79.9% 77.0% -390 bps -160 bps 44.0% 40.1% 42.6% 41.0% -110 bps -50 bps 32.2% 31.1% 30.

79.9%

FY25 Gross Profit Margin (%) EBIDTA Margin (%) PAT Margin (%) -190 bps -290 bps 80.4% 78.5% 79.9% 77.0% -390 bps -160 bps 44.0% 40.1% 42.6% 41.0% -110 bps -50 bps 32.2% 31.1% 30.5% 30.

Investor Relations Advisor

1

Investor Relations Advisor

Concord Biotech Limited Concord Biotech Limited CIN: L24230GJ1984PLC007440 CIN: L24230GJ1984PLC007440 Mr. Lalit Sethi – Chief Financial Officer Mr. Lalit Sethi – Chief Financial Officer lalitsethi@concordbiotech.com lalitsethi@concordbiotech.com www.concordbiotech.com www.concordbiotech.com Strategic Growth Advisors Pvt. Ltd. Strategic Growth Advisors Pvt. Ltd. CIN - U74140MH2010PTC204285 CIN - U74140MH2010PTC204285 Mr. Jigar Kavaiya / Mr. Sagar Shroff Mr. Jigar Kavaiya / Mr. Sagar Shroff jigar.kavaiya@sgapl.net / sagar.shroff@sgapl.net jigar.kavaiya@sgapl.net / sagar.shroff@sgapl.net +91 99206 02034 / +91 98205 19303 +91 99206 02034 / +91 98205 19303 www.sgapl.net www.sgapl.net